This NDC is on FDA's drug shortage list (posted Mar 13, 2023)
Product Information
METHOTREXATE 50 MG/2 ML VIAL is a generic product labeled by Hospira Inc., priced at $3.1832 per ML under NDC 61703035010. Its NADAC has been published 330 times since Jun 10, 2020.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AP.
Strength
25 mg/mL
Manufacturer
Hospira Inc.NDC
61703035010
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
INTRAMUSCULAR; INTRAVENOUS; SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
METHOTREXATE SODIUMApproval Type
New Drug (NDA)
FDA Application
NDA011719FDA Approved
Before 1982
TE Code
AP
On Market Since
9/25/2014
Pharmacological Classes
Price Statistics
The NADAC for METHOTREXATE 50 MG/2 ML VIAL has been published 330 times since Jun 10, 2020, and over the history we have for it it has declined 4.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.1832 per ML |
|---|---|
| All-time high | $3.4029 (Feb 16, 2022) |
| All-time low | $2.6573 (Jul 17, 2024) |
| 52-week high | $3.3602 |
| 52-week low | $3.1283 |
| Median price | $3.1788 |
| Average price | $3.1646 |
| Largest weekly change | -20.7% (Jul 17, 2024) |
| Weeks tracked | 330 |
| Tracking since | Jun 10, 2020 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 80% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hospira Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Methotrexate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Folate Analog Metabolic Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METHOTREXATE 50 MG/2 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for METHOTREXATE 50 MG/2 ML VIAL, manufactured by Hospira Inc., is $3.1832 per ML (NDC 61703035010), effective Sep 30, 2026.
How has the price of METHOTREXATE 50 MG/2 ML VIAL changed over time?
Over the history we have for it, the NADAC for METHOTREXATE 50 MG/2 ML VIAL has declined 4.3%. It has been tracked across 330 weekly CMS publications since Jun 10, 2020.
What are the highest and lowest recorded NADAC prices for METHOTREXATE 50 MG/2 ML VIAL?
Since Jun 10, 2020, the NADAC for METHOTREXATE 50 MG/2 ML VIAL has ranged from a low of $2.6573 (Jul 17, 2024) to a high of $3.4029 (Feb 16, 2022), with a median of $3.1788 per ML.
Are there cheaper alternatives to METHOTREXATE 50 MG/2 ML VIAL?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, METHOTREXATE 1 GRAM/40 ML VIAL, is $0.6450 per ML — about 80% below METHOTREXATE 50 MG/2 ML VIAL.
Who manufactures METHOTREXATE 50 MG/2 ML VIAL?
METHOTREXATE 50 MG/2 ML VIAL (NDC 61703035010) is labeled by Hospira Inc., and CMS classifies it as a generic product.
Is METHOTREXATE 50 MG/2 ML VIAL in shortage?
Yes — NDC 61703035010 is currently listed in FDA's drug shortage database (posted Mar 13, 2023).